Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Chan, Shirley" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-10 z 17
Autorzy:
Petrosillo, Nicola
Das, Koray
Spigaglia, Patrizia
Di Bella, Stefano
Di Carlo, Isidoro
Shelat, Vishal G.
Barbut, Frederic
Kluger, Yoram
Cherry-Bukowiec, Jill R.
Kim, Jae Il
Mazuski, John E.
Cocuz, Maria Elena
Caproli, Emanuele
Ferrada, Paula
Ivatury, Rao
To, Kathleen B.
Cook, Charles H.
Clanton, Jesse
Camacho-Ortiz, Adrian
Ghnnam, Wagih
Bala, Miklosh
Sartelli, Massimo
McFarland, Lynne V.
Gomes, Carlos Augusto
LaBarbera, Francis D.
Kelly, Ciaran P.
Raza, Mansoor
Fraga, Gustavo P.
Eckert, Catherine
Portela, Francisco
Ansaloni, Luca
Forrester, Joseph Derek
Malangoni, Mark A.
Sganga, Gabriele
Cui, Yunfeng
Lee, Jae Gil
Puri, Basant K.
Ray, Arnab
Frossard, Jean Louis
Biffl, Walter L.
Lee, Yeong Yeh
Furuya-Kanamori, Luis
Humphrey, Felicia
Brecher, Stephen M.
Abu-Zidan, Fikri M.
Herzog, Torsten
Gorrepati, Venkata
Alrahmani, Layan
Viale, Pierluigi
Karamarkovic, Aleksandar
Catena, Fausto
Coccolini, Federico
Cainzos, Miguel A.
Demetrashvili, Zaza
Lohsiriwat, Varut
Marwah, Sanjay
Augustin, Goran
Juang, Paul
Kim, Peter K.
Enani, Mushira Abdulaziz
Metan, Gokhan
Bhangu, Aneel
Timsit, Jean Francois
Tattevin, Pierre
Ordonez, Carlos A.
Ben-Ishay, Offir
Galeiras, Rita
Coimbra, Raul
Velmahos, George C.
Moore, Frederick Alan
Stewart, David B.
Faro, Mario
Di Saverio, Salomone
Eiland, Edward H.
Czepiel, Jacek
Uhl, Waldemar
Canterbury, Laura A.
Khanna, Sahil
Griffiths, Ewen A.
Nord, Carl Erik
Eckmann, Christian
Dumitru, Irina Magdalena
Trana, Cristian
Eltringham, Ian
Leppaniemi, Ari
Rems, Miran
Zahar, Jean Ralph
Vassallo, Angela
Chan, Shirley
Abdelsattar, Zaid M.
Isik, Arda
Sakakushev, Boris E.
Ahmed, Mohamed Hassan
van Goor, Harry
Urbanek, Libor
Moore, Ernest E.
Ko, Wen Chien
Pereira Junior, Gerson Alves
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Autorzy:
Dimopoulos, Meletios A.
Ji, Meng
D'Sa, Shirley
Cohen, Aileen
Xu, Wei
Tam, Constantine S
Huang, Jane
Garcia-Sanz, Ramon
Roberts, Andrew W
Zhu, Jun
Li, Jianyong
Marlton, Paula
Guo, Haiyi
Song, Yuqin
Jurczak, Wojciech
Gottlieb, David J
Zhou, Lei
Munoz, Javier
Du, Chenmu
Phillips, Tycel
Novotny, William
Cull, Gavin
Owen, Roger G.
Zhu, Hongjie
Tedeschi, Alessandra
Trotman, Judith
Chan, Wai Y.
Qiu, Lugui
Opat, Stephen
Opis:
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N=779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range: 0.1-65); 16% of patients were treated for ≥3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough, pneumonia (21% each), urinary tract infection (UTI), fatigue (15% each). Most common grade ≥3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade ≥3 AEs included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%). Treatment discontinuations and dose reductions for AEs occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n=9), sepsis (n=4), unspecified cause (n=4), and multiple organ dysfunction syndrome (n=5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia : final analysis from the randomized phase III ASPEN study
Autorzy:
Dimopoulos, Meletios A.
McCarthy, Helen
Trneny, Marek
D'Sa, Shirley
Cohen, Aileen
Motta, Marina
Mulligan, Stephen
Wahlin, Bjorn E.
Schneider, Jingjing
Tam, Constantine S.
Fernández de Larrea, Carlos
Garcia-Sanz, Ramon
Allewelt, Heather
Buske, Christian
Czyz, Jaroslaw
Marlton, Paula
Libby, Edward
Tani, Monica
Jurczak, Wojciech
Opat, Stephen
Siddiqi, Tanya
Patel, Sheel
Cull, Gavin
Owen, Roger G.
Leblond, Veronique
Belada, David
Castillo, Jorge J.
Tedeschi, Alessandra
Treon, Steven P.
Trotman, Judith
Chan, Wai Y.
Lee, Hui-Peng
Minnema, Monique C.
Matous, Jeffrey
Opis:
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall survival were not reached. Any-grade adverse events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.9%), atrial fibrillation/flutter (23.5% v 7.9%), and pneumonia (18.4% v 5.0%) were more common with ibrutinib versus zanubrutinib; neutropenia (20.4% v 34.7%) was less common with ibrutinib versus zanubrutinib (cohort 1). Zanubrutinib was associated with lower risk of AE-related treatment discontinuation. Overall, these findings confirm the long-term response quality and tolerability associated with zanubrutinib.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Wyświetlanie 1-10 z 17

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies